The global alopecia market is expected to grow at a CAGR of around 5.0%. In 2018, the market was valued at 8.44 billion USD. Increasing prevalence of the diseases, rising healthcare spending and increasing per capita income of the people driven the growth of the market.
The global alopecia market is segmented on the basis of types, end users, and distribution channel. On the basis of disease type, the global market is segmented into alopecia areata, and androgenetic alopecia. On the basis of end users, the market is segmented into homecare settings, dermatology clinics, and others. And on the basis of distribution channel, the market is categorized into prescriptions and OTC.
Geographical the Global Alopecia market is divided into five regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
North America leads the market with and is expected to grow lucratively over the forecast period. Presence of technologically advanced healthcare infrastructure, High disposable income and availability of novel therapeutic options affecting to the treatment are some of the factors contributing to the high market share of North America.
Europe is expected to dominate in the near future owing to outburst of middle-aged population. Asia Pacific has also witnessed growth owning to a large population suffering from Alopecia and rising awareness affecting to the available therapeutic options are the key drivers. Latin America, Middle East and Africa are expected to have a sluggish growth. However, these region are expecting a healthy market growth owing to the huge opportunity for the market growth.
Some of the leading companies operating in the global alopecia market include Cipla,Dr. Reddy’s Laboratories Ltd, Merck & Co.,Viviscal, Regaine, Ranbaxy Laboratories Ltd, Kirkland Signature, Lexington International LLC, Vitabiotics, Alpecin - Dr. Kurt Wolff GmbH & Co, Johnson and Johnson, GlaxoSmithKline PLC.
Wired Hearld provides latest all industry news and technology innovations.